COVID-19 continues to affect the care of patients with metastatic renal cell carcinoma (RCC) and other cancers in a number of ways. Oncologists are learning as much as possible about the virus to make the best treatment decisions possible for their patients.
One of the activities put in place is the COVID-19 and Cancer Consortium (CCC19) multi-hospital registry to collect data on patients with cancer who have either suspected or confirmed infection with the virus. Using this registry, health care professionals collect key information to understand trends that might potentially impact the treatment of cancer.
For example, data recently published in Cancer Discovery revealed several insights, including that hydroxychloroquine combined with any other agent was linked with increased mortality versus other COVID-19 therapies; treatment with remdesivir was shown to result in reduced mortality versus untreated controls, although not statistically significant; and African American patients were half as likely to receive remdesivir than their white counterparts.
In an interview with OncLive during the 2020 International Perspectives in Cancer webinar on Genitourinary Cancers, Dr Choueiri from the Harvard Medical School, Cambridge, USA, further discussed the effect of the COVID-19 pandemic on cancer care, as well as key updates from the CCC19.